Category: Articles

Pressure ulcers, better known as decubitus or bedsores, come across as injuries to the skin as well as the underlying tissue that is an outcome of skin being subject to prolonged pressure. They generally occur on the bony parts like the buttocks, elbow, back, ankles, heels, and shoulder. Those not able to move are more prone to pressure ulcers. If identified at early stages, sepsis, cellulitis, joint and bone infections, or cancer could be prevented, as stated by Persistence Market research in its latest market study entitled “Pressure Ulcer Devices Market”. This is where pressure ulcer devices play an active role … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Pressure injuries are common among patients who experience extended exposure to pressure on a bony prominence or shear to areas of poor turgor, two factors that lead to constriction of a patient’s blood supply to the exposed area. A patient who is bedridden or has certain chronic conditions, such as diabetes,1 is more likely to develop a pressure injury. When mechanical force is imposed on the skin, it can result in poor blood flow and damage to the bone-muscle interface, thus making tissue sensitive and painful. For patients with limited mobility, this can be especially frustrating because they may not be able to adjust positions or medical equipment. If pressure injuries are left untreated or unnoticed, they can also become infected and even enter muscle and bone. Risk assessment tools are available to assess pressure injury risk and can work in tandem with practice standardization, thereby leading to effective treatment plans for practitioners and patients … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Lessons Learnt From a National Referral Hospital in Indonesia

 

Abstract
Background: Diabetic foot ulcer (DFU) is one of the most terrifying diabetic complications for patients, due to the high mortality rate and risk for amputation. During the COVID-19 pandemic, many diabetic patients limited their visits to the hospital, resulting in delays for treatment especially in emergency cases.

 

Objective: This study aimed to compare the characteristics of patients with DFU pre- and during COVID-19 pandemic period. Methods: This study was a retrospective cohort study using foot registry data. We compared our patients’ characteristics pre-COVID-19 pandemic period (1 March 2019-28 February 2020) and during COVID-19 pandemic period (1 March 2020-28 February 2021).

 

Results: Cohorts of 84 and 71 patients with DFU pre- and during COVID-19 pandemic period, respectively, were included in this study. High infection grade (66.7% vs 83.1%, P = .032), osteomyelitis event (72.6% vs 87.3%, P = .04), leukocyte count (15 565.0/μL vs 20 280.0/μL, P = .002), neutrophil-to-lymphocyte ratio (7.7 vs 12.1, P = .008), waiting time-to-surgery (39.0 h vs 78.5 h, P = .034), and number of major amputation (20.2% vs 39.4%, P = .014) were significantly higher during the COVID-19 pandemic period.

 

Conclusion: During the COVID-19 pandemic, patients with DFU had more severe infection, higher proportion of osteomyelitis, longer waiting time for getting surgical intervention, and higher incidence of major amputation.

 

Keywords: COVID-19; amputation; diabetic foot ulcer; infection; mortality; waiting time to surgery.
… from PubMed

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

A person formerly incarcerated at the Allegheny County Jail has filed a lawsuit against multiple members of the jail’s medical staff alleging that a lack of medical treatment in the facility led to the amputation of his leg … In 2011, McCray was shot in the spine, which caused him to lose one of his kidneys and develop a drop foot, which due to dragging of the foot and numbness, made him more susceptible to developing ulcers on his foot, the lawsuit said … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

86 year old female Ankle Wound – Pyoderma Gangrenosum After four years of treating using Santyl, honey, silver products, alginates, Aquacel Ag, Bactroban, sharp debridement, etc. Positive biopsy for PG, Autoimmune disease (lupus) common comorbidity associated with PG A home health, wound-care nurse treated 1.5 years Patient now self-treating Occasional visit to rheumatologist 40 mg of oral steroids Wound healed in only 5 months with Pure&Clean

RedDress, a Florida-based Israeli medical company is shipping revolutionary blood-clotting wound care systems to Ukraine to help with serious injuries and severe trauma wounds … RedDress began shipments of 400 of their ActiGraft systems this week to multiple hospitals in Ukraine to help treat civilian casualties as a result of the indiscriminate Russian attacks … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Kristin Fuller, MD
Mr. K. was a 37-year-old male who I saw in my clinic for uncontrolled type-2 diabetes. Every time he came in, his HbA1c and rapid glucose were off the charts. He had multiple hospital admissions for diabetic ketoacidosis, and already had two toes amputated due to severe peripheral arterial disease, a known diabetes complication … One day, a surgeon called to inform me that Mr. K. was in the hospital and would be undergoing a below-the-knee amputation (BKA) due to extremely poor circulation as a result of poor glycemic control. The surgeon initially tried to blame me for not having my patient on the proper diabetic regimen. I explained that I had consistently tried to work with Mr. K., and he was stubbornly non-compliant with his diet and insulin regimen … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Results from a Phase 3, Multicentre, Randomized, Active-controlled, Parallel-group Study

 

Diabetic foot ulcer (DFU), if untreated, accounts for lower-limb amputations affecting patients’ quality-of-life. Diperoxochloric acid (DPOCL) is known to heal DFU by its antibacterial and fibroblast stimulating activity. This was a phase 3, multicentre, randomized, double-blind, active-controlled, parallel-group study conducted to evaluate the efficacy and safety of topic solution of DPOCL compared with isotonic sodium chloride solution (ISCL). Adult patients with type 1 or 2 diabetes with random blood glucose levels of <250 mg/dL, with ≤ than three full-thickness foot ulcers were enrolled. Primary efficacy endpoint was complete wound closure and secondary was wound surface area. Adverse events were analyzed as safety endpoint. Of 311 enrolled patients, 289 were randomized … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Chronic Diabetic Foot Ulcers through Modifications of Infection, Angiogenesis, Macrophage Phenotype and Neutrophil Response

 

This work aimed to evaluate the adjuvant treatment to surgical debridement using topical applications of Lactiplantibacillus plantarum ATCC 10241 cultures in complicated diabetic foot ulcers as compared to diabetic foot ulcers receiving surgical wound debridement. A randomised controlled trial was performed involving 22 outpatients with complicated diabetic foot ulcers that either received surgical debridement (SuDe, n = 12) or surgical debridement plus topical applications of L. plantarum cultures (SuDe + Lp, n = 10) every week during a 12 week treatment period. Compared to patients receiving SuDe, patients treated with SuDe + Lp exhibited significantly increased fibroplasia and angiogenesis, as determined by Masson’s trichrome staining and the study of CD34 cells, α-smooth muscle actin to semi-quantify vascular area, number of vessels and endothelial cells. In addition, a promotion of the polarisation of macrophages from M1 (CD68) to M2 (CD163) phenotype was observed in SuDe + Lp patients with remarkable differences in the tissue localisation … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Dedee F. Murrell, MD, details the EASE trial findings presented at AAD 2022, and what the benefit of the novel topical gel may mean for patients with EB

 

A new phase 3 trial assessing a novel topical gel for the treatment of young patients with epidermolysis bullosa (EB) wounds show the birch bark-based product achieved nearly 50% heal of targeted wounds over 12 months … The interim EASE findings, presented in a late-breaking session at the American Academy of Dermatology (AAD) 2022 Annual Meeting in Boston, show birch triterpenes (Oleogel-S10) may provide a unique and broadly-applicable benefit for patients with rare, often deadly skin condition … In an interview with HCPLive at AAD 2022, study author Dedee F. Murrell, MD, director of dermatology at St. George Hospital, USNW, discussed the clinical history of Oleogel S-10 leading … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

chronic wounds proven by gold-standard trial

 

Comparative clinical trial shows significant improvement in wound closure and infection control based on treatment with the plasmajet kINPen® MED from neoplas med compared to best practice wound care – cost-effectiveness analysis proves high cost-savings by innovative technology

 

GREIFSWALD, Germany and FELDKIRCH, Austria, March 22, 2022 /PRNewswire/ — The results of a randomized controlled trial (RTC) may offer new opportunities for the approximately two million patients with chronic wounds solely in Germany: The innovative cold atmospheric plasmajet (CAP-jet) technology showed significantly more healing progress in chronic wounds in comparison to best practice (BP) modern wound care at two study centers. Within six weeks, 59 percent of all wounds healed completely under cold plasma treatment compared to only 5.1 percent in patients under BP therapy. Time to complete healing was also considerably shorter under CAP-jet treatment, and wound infections were overcome statistically significant more rapid. With a very good tolerability profile, an economic analysis of the study data also showed a cost saving of 65 percent for the dressing material alone compared to the BP group. The study data were recently published in the journal Nature Scientific Reports.

 

Acceleration of wound healing and wound closure proven

In the study conducted by Prim. Univ.-Professor Robert Strohal, head of the Department of Dermatology and Venereology at the Federal Academic Teaching Hospital Feldkirch, the cold plasma procedure of the Greifswald-based company neoplas med GmbH was scientifically examined in wound care. For this purpose, he compared treatment with the CAP-jet kINPen® MED at the Austrian Federal Academic Teaching Hospitals Feldkirch and Bregenz with current best practice treatment in 78 patients with infected and non-infected wounds. ‘This study was the first to investigate the exclusive effect of tissue accessible cold plasma on wound healing and infection control without the use of an additional standard therapy,’ said Prim. Univ.-Prof. Strohal.

 

After treatment with the CAP-jet, the proportion of healthy tissue increased significantly faster than under the BP treatment and the wounds under CAP-jet therapy also healed significantly faster. At the end of the study, the wound area in the CAP group had reduced by 94.7 percent compared to the baseline value, in the comparison group it was only 56.3 percent. CAP also proved superior in terms of infection control. In contrast to BP therapy, all wounds infected at the start of the study showed complete resolution of infection signs. In addition, the signs of infection disappeared significantly faster under cold plasmajet therapy.

 

Patients’ quality of life can improve

Ulrike Sailer, CEO of the company neoplas med GmbH in Greifswald/Germany, explained: ‘The Joint Federal Committee (Gemeinsamer Bundesausschuss, G-BA) as the central decision-making body of the German health care system already recognized last year the potential of cold plasma for the innovative treatment of chronic wounds at our request. Therefore, the G-BA decided to carry out an observational trial for testing with the aim of obtaining health insurance approval. The results of the clinical trial that now have been published clearly demonstrate the superiority of the CAP-jet kINPen® MED compared to BP wound care. These results provide further evidence for the high clinical relevance of the CAP-jet precision technology. At the same time, it represents important news for millions of people who suffer from chronic wounds for years.’

 

Chronic wounds are often associated with high morbidity and considerable impairments in everyday life as well as the patients’ psyche. Faster wound healing and thus a shorter therapy duration by using the plasmajet kINPen® MED can therefore significantly improve the patients’ quality of life. Furthermore, a lower burden by pain during treatment can be observed, and a reduced number of dressing changes can be assumed. Patients confirmed the very good tolerability and even described the treatment as pleasant in the majority of cases.

 

Significant advantage in treatment costs

A cost-effectiveness analysis based on the available study data showed that 21.4 percent fewer physician visits and 34.3 percent fewer dressing changes were necessary in the CAP-jet group compared to BP. The savings alone in dressing material resulted in a cost advantage for CAP-jet therapy of 64.7 percent compared to BP. Previously, average costs of 10,000 € per patient and year were assumed. Ulrike Sailer: ‘Thus, the cold plasmajet kINPen® MED offers not only a more efficient and tolerable technology, but also opens up the opportunity for significantly higher cost-effectiveness in the treatment of chronic wounds.’

 

Further information material can be found under the following link: https://1drv.ms/u/s!Aph6cOwNbPEJgQCIbClSETCZ_lal?e=BvkuGi

 

Background Information:

The study included 78 patients with wounds up to 10 x 20 cm in size and existing for at least 6 weeks. The patients were randomized in a 1:1 ratio into two groups and treated for the study duration of 6 weeks either with the CAP-jet kINPen® MED (30 seconds per cm2 wound area) or suitable wound dressings according to BP wound care. Only one wound per patient was evaluated.

 

With regard to the treatment regime, CAP-jet therapy was administered 3 times in the 1st week in the CAP group, 2 times in the 2nd week and once a week in the following observation period; furthermore, the wounds were covered with gauze and a secondary dressing. In contrast, the BP group was treated with a wound phase-adapted dressing; infected wounds were additionally cleaned with an antiseptic. In both groups, patients with venous ulcers received compression therapy. The primary endpoint of the study was the amount of granulation tissue at the end of the study. In addition, cold plasma effects on wound infection, wound area, healing time, wound pH and exudate volume (wound fluid) as well as local tolerability were investigated.

 

Improvement in wound infection: All 13 wounds infected at baseline in the CAP-jet group showed complete resolution of infection signs without the need for additional antiseptics. In contrast, 4 of the 18 wounds infected at baseline in the BP group showed no improvement despite the use of antiseptics. Furthermore, the signs of infection decreased significantly faster under CAP-jet therapy compared to BP therapy. These data confirm the previously published evidence on the good antimicrobial efficacy of CAP.

 

Cold plasma is a gas containing ionized atoms, ions and electrons that has been shown to disinfect wounds and activate the wound healing process. With its fine jet, the plasmajet kINPen® MED enables highly precise treatment in anatomically and pathologically challenging areas under visual control and without touching, which is not possible with other wound therapies.

 

About neoplas med GmbH

neoplas med GmbH was founded in 2009 as a spin-off of the Leibniz Institute for Plasma Science and Technology e. V. (INP) in Greifswald, Germany. Ulrike Sailer took over the position of managing director at the end of 2019. Based on the INP research into plasma medicine, the emerging company develops innovative products for medical applications. The first product developed on this basis is the CE-marked kINPen® MED atmospheric pressure plasmajet, the first internationally approved and marketed plasmajet for the treatment of chronic wounds and pathogen-induced skin disorders. It is the result of a long-lasting cooperation with the INP institute, the university hospital of Greifswald, Germany, the Charité hospital of Berlin, Germany, and various industrial partners. In July 2021, the Federal Joint Committee, as the central decision-making body in the self-governing health care system, decided on a trial study with the cold plasmajet procedure and thus took an important step towards reimbursement by the health insurance companies.

 

About kINPen® MED

The plasmajet kINPen® MED is the first atmospheric pressure plasmajet to receive CE approval for the treatment of chronic wounds and pathogen-induced skin disorders. The plasmajet applies a physical cold plasma with a temperature of < 40 degrees Celsius with pinpoint precision and without wound contact. Areas with an uneven profile, recesses or cavities can be reached easily and treated evenly. The noble gas argon used for the generation of the plasma provides a controlled atmosphere around the generated plasma beam, thus ensuring a consistent high treatment quality.

 

Press contact

Claudia Kerber
Phone: +49 3834 515 201
Mobile: +49 (0)162 23 770 70
claudia.kerber@neoplas-med.eu
neoplas med GmbH
Walther-Rathenau-Straße 49a, 17489 Greifswald, Germany

By Chase Doyle
If untreated or unsalvageable, the diabetic foot requires surgical interventions to address the risks to its viability. However, recent advancements in the field suggest that surgeons may not always have to sacrifice a limb to save a life.

During the 2021 virtual American College of Surgeons Clinical Congress, Lucas M. Ferrer, MD, described the use of endovascular venous arterialization for limb salvage, and William P. Robinson, MD, discussed the timing of foot amputation after revascularization … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Providing Renewed Hope for World’s Largest Diabetic Foot Ulcer Population

 

OCEANSIDE, Calif., March 23, 2022 /PRNewswire/ — Advanced Oxygen Therapy Inc. (AOTI), the global leader in noninvasive topical oxygen wound healing solutions, announced today that is has received Chinese National Medical Products Administration (NMPA), commonly referred to as China FDA, approval for its unique cyclically pressurized Topical Wound Oxygen (TWO2) therapy. Making it the only advanced sustained wound healing therapeutic to have achieved such a designation and allowing the company to now commence marketing in China with its local partner.

 

China has the world’s largest Diabetic and resultingly Diabetic Foot Ulcer (DFU) population. The International Diabetes Federation estimates that 10.6% of the Chinese adult population now have diabetes that equates to 141 million people. This represents a 56%, or 50 million person, increase in the last 10 years alone.1 In China, the annual incidence of DFU and Amputation has recently been reported to be 8.1% and 5.1% respectively, representing a staggering 11.4 million ulcerations and 7.2 million preventable lower extremity amputations every year.2

 

AOTI’s globally patented TWO2 homecare therapy has been demonstrated in recently published high-quality Randomized Controlled Trial 3 and Real Word Evidence 4 studies to provide more durable complete DFU healing. Resulting in six-fold reductions in ulcer recurrence, with an unprecedented 88% reduction in hospitalizations and 71% reduction in lower extremity amputations seen over 12 months. Such sustained healing provides patients with renewed hope of limb preservation, while offering significant reductions in healthcare resource utilization with resultant health economic savings.

 

Professor Andrew Boulton, past-President of the European Association for the Study of Diabetes and Professor of Medicine at the University of Manchester, UK and University of Miami, USA, and Chairman of AOTI’s Scientific and Clinical Advisory Board, commented: “Diabetes is one of the fastest growing global health emergencies of the 21st century. It is a real game-changer to finally have clinically proven homecare therapeutics like TWO2 available that make meaningful impact in such critical outcomes as hospitalizations and amputations. Now that TWO2 therapy is authorized in China, the world’s largest diabetic foot ulcer population has a renewed hope for better outcomes.”

 

1 International Diabetes Federation. IDF Diabetes Atlas, 10th Edition. Brussels, Belgium: 2021. Available at: https://www.diabetesatlas.org

 

2 Development and validation of a brief diabetic foot ulceration risk checklist among diabetic patients: a multicenter longitudinal study in China. Zhou, Q., Peng, M., Zhou, L. et al. Nature, Sci Rep 8, 962 (2018). https://doi.org/10.1038/s41598-018-19268-3

 

3 Multinational, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy of Cyclical Topical Wound Oxygen (TWO2) Therapy in the Treatment of Chronic Diabetic Foot Ulcers; The TWO2 Study. Robert G. Frykberg et al, Diabetics Care 2020; 43:616-624. https://doi.org/10.2337/dc19-0476.

 

4 Reduced Hospitalizations and Amputations in Patients with Diabetic Foot Ulcers Treated with Cyclical Pressurized Topical Wound Oxygen Therapy: Real-World Outcomes; Jessica Izhakoff Yellin, et al; Advances in Wound Care 2022; http://doi.org/10.1089/wound.2021.0118

 

About AOTI
AOTI is a privately-owned company based in Oceanside, California USA and Galway, Ireland that provides innovative solutions to resolve severe and chronic wounds worldwide. Our products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. Our patented non-invasive Topical Wound Oxygen (TWO2) homecare therapy is clinically proven to deliver Sustained Wound Healing that reduces both Amputations and Hospitalizations, So Life Can Get Back to Normal.

 

For more information see: www.aotinc.net
Dr. Mike Griffiths
CEO & President
332487@email4pr.com
(760) 672 1920
SOURCE AOTI Inc.

Janet Falade, PharmD Candidate, South College School of Pharmacy

 

The increased risk of having type 2 diabetes (T2D) and cardiovascular disease (CVD) has been a significant concern in the health care sector worldwide. Also, it has been regularly reported by the World Health Organization (WHO) that cardiovascular diseases (CVDs) and diabetes mellitus are part of the ten major leading causes of death globally. Some changes, such as increased blood pressure, cholesterol, and blood sugar level, are usually apparent before the onset of these diseases. Therefore, early detection of individuals at increased risk of having this disease is essential in preventing the disease Incidence. Furthermore, these diseases can influence specific measures like lifestyle changes such as healthy diet and exercise. In addition, machine learning models can help predict the risk of having T2D and CVD. Other factors such as lipid level and blood sugar levels, particularly evaluation of gene variations, protein complements, and metabolome, which includes lipidome, may aid in identifying physiopathology pathways that might be … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Debridement is the process of removing nonviable tissue and foreign objects (such as glass or shrapnel) from a wound bed to help the wound heal.1 Decaying tissue can trap bacteria and lead to a harmful infection such as gangrene, which is the death of body tissue resulting from a lack of appropriate blood flow or in response to a severe bacterial infection.2 Debridement is thus critical to effective wound management … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Antimicrobial Action, and in vivo Effect for Enhancing Wound Healing in Diabetic Rats

May Almukainzi, Thanaa A El-Masry, Walaa A Negm, Engy Elekhnawy, Asmaa Saleh, Ahmed E Sayed, Mohamed A Khattab, Dalia H Abdelkader

Download full article (PDF)

Purpose: Gentiopicroside (GPS), an adequate bioactive candidate, has a promising approach for enhancing wound healing due to its antioxidant and antimicrobial properties. Its poor aqueous solubility negatively affects oral absorption accompanied by low bioavailability due to intestinal/hepatic first-pass metabolism. Our aim in this study is to fabricate GPS into appropriate nanocarriers (PLGA nanospheres, NSs) to enhance its solubility and hence its oral absorption would be improved.

 

 

Methods: Normal and ODS silica gel together with Sephadex LH20 column used for isolation of GPS from Gentiana lutea roots. Crude GPS would be further processed for nanospheres fabrication using a single o/w emulsion solvent evaporation technique followed by in vitro optimization study to examine the effect of two formulation variables: polymer (PLGA) and stabilizer (PVA) concentrations on the physical characterizations of prepared NSs. Possible GPS-PLGA chemical and physical interactions have been analyzed using Fourier-transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC). The optimum GPS-PLGA NSs have been chosen for antimicrobial study to investigate its inhibitory action on Staphylococcus aureus compared with unloaded GPS NSs. Also, a well-designed in vivo study on streptozotocin-induced diabetic rats has been performed to examine the wound healing effect of GPS-PLGA NSs followed by histological examination of wound incisions at different day intervals throughout the study.

 

 

Results: The optimum GPS PLGA NSs (F5) with well-controlled particle size (250.10± 07.86 nm), relative high entrapment efficiency (83.35± 5.71), and the highest % cumulative release (85.79± 8.74) have increased the antimicrobial activity as it exhibited a higher inhibitory effect on bacterial growth than free GPS. F5 showed a greater enhancing impact on wound healing and a significant stimulating effect on the synthesis of collagen fibers compared with free GPS.

 

Conclusion: These findings demonstrate that loading GPS into PLGA NSs is considered a promising strategy ensuring optimum GPS delivery for potential management of wounds … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

North Texas researchers hope their development will help ward off diabetic foot ulcers, which can lead to amputation.
Research scientists at The University of Texas at Arlington have developed footwear technology that may prevent the development of diabetic foot ulcers … People with diabetic neuropathy deal with numbness in their legs and feet and are often unable to detect and respond to stress-related pain by adjusting their foot loading … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

by Richard Payerchin
Work-life balance is the most important factor for new physicians choosing their first jobs – possibly as a result of dealing with stresses brought on by COVID-19, according to a new survey … The responses confirmed and surpassed a similar finding from a study of 2018, according to health staffing consultant CHG Healthcare. The company announced the survey from its CompHealth division, which surveyed 145 physicians who had been out of residency for two to three years … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

TAMPA, Fla., March 16, 2022 /PRNewswire/ — Leading wound care management and clinical services provider, WoundGenex, today announced a strategic partnership with MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX”), a transformational placental biologics company, to launch an exclusive version of WoundGenex’s Premier Graft Program to its clients across the country, providing clinicians access to industry-leading allograft products through a convenient purchasing option.

 

WoundGenex Partners with MIMEDX to Launch the first-of-its-kind Premier Graft Program.
The partnership adds the portfolio of MIMEDX advanced wound care products to the list of treatment options available to clinicians who rely on WoundGenex’s expertise in clinical documentation requirements, wound care revenue cycle, and reimbursement policies. Premier Graft Program members tap into group purchasing power that allows WoundGenex to facilitate product ordering at no upfront cost to the provider or organization. WoundGenex Program Liaisons work with providers and billing specialists to help streamline the entire process, including proper utilization of products, documentation of medical necessity, coding, and coding education, and more. A first-of-its-kind program, no payment is due from the ordering providers until reimbursement is realized on the product.

 

MIMEDX is a leading provider of placental allografts in the Cellular Tissue Products/Skin Substitute segment of the advanced wound care category. MIMEDX’s flagship advanced wound care product, EPIFIX®, is covered by 100% of national commercial payors for the treatment of diabetic foot ulcers, totaling over 300 million covered lives.

 

“WoundGenex is thrilled to be able to partner with MIMEDX to introduce a meaningful solution to providers to maximize clinical and reimbursement outcomes. Clinical expertise, industry leading advanced wound care products, and a strong understanding of reimbursement across all sites of service is the key for a successful practice,” said WoundGenex President and Co-founder, Thomas Smith.

 

“In partnering with WoundGenex, we are able to further substantiate our mission to increase access to innovative technologies for patients and customers alike,” said Rohit Kashyap, Ph.D., MIMEDX Chief Commercial Officer. “We are excited for the opportunity this program will provide to ensure more patients receive the care they need, as well as the opportunity to continue strengthening our reimbursement and service offerings for clinicians who choose our products.”

 

About WoundGenex
Founded in 2014 in Tampa, Florida, WoundGenex optimizes the way clinicians provide wound care to their patients in various places of service such as physician practices, hospitals, surgical centers, nursing homes, free-standing wound centers across the country. Thanks to more than two decades of experience in both the clinical and administrative aspects of wound care WoundGenex provides true solutions to help meet the challenges of providing best-in-class care from start to finish – from clinical and operational excellence to financial and procedural optimization.

 

To learn more about WoundGenex and the Premier Graft Purchasing Program, please visit https://woundgenex.com.

 

Media Inquiries: Media@WoundGenex.com

 

About MIMEDX
MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental tissue engineering, we have both a commercial business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit https://MIMEDX.com

 

MIMEDX Contacts

 

Investors:
Jack Howarth
Investor Relations
404.360.5681
jhowarth@mimedx.com

 

Media:
Hilary Dixon
Corporate & Strategic Communications
404.323.4779
hdixon@mimedx.com

 

Cision View original content:https://www.prnewswire.com/news-releases/woundgenex-partners-with-mimedx-to-launch-premier-graft-program-to-wound-care-providers-nationwide-301503626.html

 

SOURCE WoundGenex

by Teresa Carvalho MSc
The pivotal Phase 3 VIITAL clinical trial of EB-101, Abeona Therapeutics’ experimental cell therapy for wound healing in people with recessive dystrophic epidermolysis bullosa (RDEB), has met its enrollment target.

The company also announced that top-line results from the VIITAL trial (NCT04227106) are expected in the in third quarter of this year … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

New Orleans, LA
March 24 – March 27
Astor Crowne Plaza
Brochure

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

To understand the concepts of a wound and wound healing, we must examine the skin and its pathophysiology, as well as its unique structures and functions. Skin care and wound management must be grounded in a comprehensive knowledge base of the structure and functions of the skin. The skin is the largest organ of the body, covering approximately 18 square feet and weighing about 12 pounds, or up to 15% of total adult body weight. It requires one-third of an individual’s circulating blood volume to sustain it. Normal surface skin temperature is 92 degrees, compared with a core body temperature average of 98.6 degrees … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Manesh Patel MD, Christopher Granger MD and Larry Allen MD

 

One thing that you mentioned about risk factors is interesting, and I’m going to ask Larry, how do you usually think about comorbidities, including heart failure? I tell our fellows in clinic, if the patients don’t smoke and don’t have diabetes, those are overrepresented in PAD [peripheral artery disease]. This comes from data that are a bit older, but the PARTNERS study where they evaluated patients doing an ABI [ankle-brachial index] in primary care clinics, about 7000 patients, and they found that a quarter of them had PAD. If they were 50 years old and over, they tested whether they had diabetes and tobacco use, or over 70. Unrecognized PAD probably exists in about a quarter [of patients] in our primary care clinics, and it fits with these comorbidities … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Diabetic foot ulcers can be extremely challenging to treat and are associated with a high morbidity and mortality. A recent large randomised controlled trial (RCT), undertaken in the US, found that a single application of a fetal bovine acellular dermal matrix plus standard of care (SOC) is a faster and more effective treatment for these ulcers than SOC alone. This masterclass will explore this evidence base and debate how to optimise use of this dermal scaffold for this indication.

 

Wed, Mar 23, 2022 · 2:00 PM · EDT

 

John C. Lantis II
Chief of Surgery, Mount Sinai West Hospital

register

Michael S. Miller DO, • Lindsey Markey RN, BSN • Regina Yoder RN • Kevin Powers DPM• TCC Kits provided by M-Med

 

Introduction:
It is well stated in the literature that Total Contact Casting (TCC) is a standard of care for off-loading of neuropathic ulcers of the plantar surface. Another standard of care is to provide a moist wound healing environment. Evidence to support appropriate wound dressings under TCC is currently unavailable despite recognition that the wound environment and thus the amount of drainage changes as the wound progresses towards healing. This pilot case series of three patients with plantar based diabetic neuropathic ulcers uses two dressings, a five layer silicone foam with absorbent polymer and moisture retentive backing dressing (SF)* for low to moderate drainage and a non-adherent super-absorbent (SAP)† polymer dressing for moderate to high exudate levels.

 

Clinical Problem:
Many TCC kits include a generic, open-cell, polyurethane foam dressing (OCF). These dressings do not absorb or retain fluid in a moderate to high exudate environment which can lead to maceration and non-healing. Furthermore, due to the high moisture vapor transmission rate of OCF, wounds with low exudate may experience desiccation and result in the development of slough and biofilm.1

 

Methods:
This pilot case series evaluates the performance of two dressings under a TCC‡. The 1st dressing is a five-layer silicone foam with super-absorbent polymer and moisture retentive backing for low to moderately exuding wounds (SF)*. The 2nd dressing is a non-adherent absorbent (SAP)† polymer dressing for moderate to high exudate levels. A total of 3 Wounds were assessed, cleansed, debrided if necessary, categorized by exudate level, and TCC was applied for 7 days. The expected outcomes were to avoid maceration, increase in healthy granulation/epithelial tissue, and achieve maximum wear time of TCC.

 

Results:
All three of the pilot cases healed completely in acceptable time with no untoward complications. The important feature was that the changes in the amounts of drainage which were identified as the healing progressed were compensated for by changing the dressings based on the amounts of exudate identified. This effectively minimized associated peri-wound maceration, damage to the increasing granulation tissue and improved tolerance of their feet to the total contact casting.

 

Conclusion:
TCC kits should consider including dressings for low-moderate and moderate-high exudate and cease adding the one-dressing-fits-all generic foam into the kit. Additionally, although foam dressings are lumped into single category, their individual traits such at total volume handling, exudate retention, and MVTR have erratic variation in function. The SF in this case series exceeded expectation and can be a standard of care unless exudate overwhelms the dressing in the 7 day expected wear. At that time, SAP should be used in place of SF to manage high exudate. Our experience is that this combination of dressings progresses wounds towards healing, enhances the clinical benefits and wear time of TCC, and decreases the potential for wound healing complications.

 

Case History 1 45 year old Insulin-dependent diabetic male (IDDM) with a history of poor compliance presented with a plantar ulcer of 2 years duration. He had developed an acute Charcot’s Arthropathy, misdiagnosed as osteomyelitis and had surgery to remove “infected” bone. He had ongoing significant drainage with periwound skin maceration and no evidence of healing.	Course of Treatment: Aggressive debridement of the ulcer was performed with identified bone at the base of the ulcer. However, further workup did not demonstrate osteomyelitis. He was placed in a TCC and SAP used due to concerns about the excessive drainage. With the drainage controlled, maceration resolved and offloading successfully managed, he went on to heal completely.
Case History 2 64 year old IDDM with a history of a Diabetic Neuropathic foot ulcer of the plantar heel. He had undergone surgery years before leaving him with a soft tissue deformity predisposing him to recurrent ulcers.	Cource of Treatment An aggressive debridement was performed with no bone exposure noted. He had moderate serous drainage from the ulcer and so SF was used to control the drainage without creating a dry wound base. TCC was performed weekly with changes of the SF dressing. With the drainage controlled and offloading accomplished, he went on to heal completely.
Case History 3 A 64 year old female with advanced rheumatoid arthritis and foot deformity presented with a 6 month history of a nonhealing ulcer of the right plantar foot. A surgery to correct this had incisional dehiscence. Topical dressings and an offloading boot were previously used unsuccessfully.	Course of Treatment An aggressive debridement was performed with no bone exposure noted. Her significant serous drainage was treated with SAP and TCC applied weekly for offloading. Over the next several weeks, the drainage decreased and the dressing was changed to SF due to decreasing wound drainage. With the drainage controlled and offloading in place, she went on to heal completely.

References
1. Hurlow J, Couch K, Laforet K, Bolton L, Metcalf D, Bowler P. (2015) “Clinical Biofilms: A Challenging Frontier in Wound Care”. Adv Wound Care (New Rochelle) 4(5): 295–301.
* KerraFoam is a registered trademark of Crawford Woundcare Ltd. † KerraMax Care is a registered trademark of Crawford Woundcare Ltd.
‡ Total Contact Casting Kits by M-Med, Mebane, NC., supplied at no charge for this case series.
This poster abstract is funded and supported by Crawford Healthcare Inc.
© Copyright Crawford Healthcare Ltd, 2016. This literature and product report is supported and funded by Crawford Healthcare Ltd. 2016

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Researchers at the Royal College of Surgeons in Ireland (RCSI University of Medicine and Health Sciences, along with collaborators in Germany and Switzerland, say their work has revealed new information about how blood clots are formed during wound healing. Their study “Platelets drive fibronectin fibrillogenesis using integrin αIIbβ3”, which appears in Science Advances, examines the behavior of platelets at a wound site, specifically their ability to sense where within a blood clot they are and remodel their surroundings accordingly … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

A team led by Maria Leptin has shown in the fruit fly Drosophila that autophagy, a mechanism of stress responses in cells, plays an important role in wound healing: When a wound heals, the process of autophagy is initiated and regulated by the protein complex TORC1. This is a newly discovered function of autophagy and the first evidence that autophagy controls the formation of syncytia (multinucleated cells). While syncytia are also formed during the development of muscles or the placenta, their role in wound healing and the involvement of autophagy are new discoveries. The article, ‘Autophagy-mediated plasma membrane removal promotes the formation of epithelial syncytia’ has been published in The EMBO Journal … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

RedDress, a privately held U.S. and Israel-based wound care company, announced today it has been awarded a group purchasing agreement with Premier Inc. This agreement allows Premier members, at their discretion, access to RedDress’ wound care product, ActiGraft® system … ActiGraft is the first wound care product that enables health care providers to produce—in real time—an in vitro blood clot from a patient’s own blood. Once applied, the blood clot serves as a protective covering and supports the body’s natural wound healing response. ActiGraft can be used for a wide variety of hard-to-treat chronic wounds, including diabetic foot ulcers, pressure injuries, venous ulcers, traumatic wounds, and post-surgical wounds … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

of EB-101 in RDEBTopline data from VIITAL™ expected in the third quarter of 2022
Abeona Therapeutics (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that target enrollment has been achieved in its pivotal Phase 3 VIITAL™ study. The objective of VIITAL™ is to evaluate the safety and effectiveness of Abeona’s investigational EB-101 product for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare connective tissue disorder characterized by severe skin wounds that cause pain and can lead to systemic complications impacting the length and quality of life. Large chronic wounds typically do not heal spontaneously and inflict the greatest pain and clinical burden on RDEB patients. Large chronic wounds treated in VIITAL™ measured greater than 20 cm2 of surface area and had remained open for more than six months. In a phase 1/2a study conducted at Stanford University, large chronic wounds treated with EB-101 showed considerable wound healing and reduction in associated long-term pain for up to six years … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

for Diabetic Foot Ulcer Infections
Microbion Corporation today announced that the US Patent and Trademark Office (USPTO) issued United States Patent No. 11,207,288 to Microbion on December 28, 2021, with claims to the use of Microbion’s proprietary pravibismane topical composition for diabetic foot infections (“DFI”). The patent, entitled “Bismuth-thiol compositions and methods for treating wounds,” extends topical pravibismane patent protection through to mid-2039. The granted claims cover the administration and use of topical pravibismane compositions in diabetic foot ulcer infections. This patent further expands Microbion’s patent portfolio, comprising granted claims to its pravibismane composition and methods of treating wounds and diabetic foot ulcers.

 

“We are pleased that the USPTO has granted this new patent supporting our pravibismane program for the treatment of diabetic foot infections,” said Dr. Brett Baker, Microbion’s President and Chief Innovation Officer. “This patent includes claims built on data from our Phase 1b clinical studies in infected patients. In these studies, topical pravibismane demonstrated a 3-fold reduction in chronic wound size compared to placebo when administered as an adjunct to standard of care treatment in patients with moderate to severe DFI. We are committed to developing novel therapies that fulfill the unmet needs caused by diabetic foot ulcer infections and faced by these patients every day.” … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

by Stephen “Andy” Rohrer, MSN, RN, APRN, AGACNP-BC, FNP-BC, CWS

I practice in West Memphis, Arkansas, about 15 miles from the city of Memphis, Tennessee. The location is suburban but the culture is rural. My people in Arkansas primarily work in farming and “blue collar” industries. West Memphis, Arkansas is separated from Memphis, Tennessee by the Mississippi River. We find that many Arkansans are simply intimidated by even the thought of crossing the bridge to go into Memphis (population about 650,000).

I am fiercely protective of my patients and our way of life here in Arkansas. I know they are hard-working, independent people who often try to fix things themselves; unfortunately, they show up for medical care only when things have progressed to dire circumstances. The drive time for patients to reach me varies from a few minutes to more than 2 hours. Our payer mix is increasingly Medicare Advantage plans … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Pain associated with chronic wounds can affect quality of life and have a major impact on physical, emotional and cognitive function. This module explores the importance of pain management, the mechanism and types of pain, as well as how to assess and manage pain.
Chronic wounds, Pain Management, Quality of life, Wound Care, Wound pain … read more

---

If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

New research led by the University of Bristol has found the protein p53 plays a key role in epithelial migration and tissue repair. The findings could improve our understanding of the processes used by cells to repair tissues, and be used to identify interventions that could accelerate and improve wound repair … Epithelial tissues are the linings that protect the body’s external skin and internal cavities, and their ability to repair themself is important. ?It is known that wounded epithelia repair themself thanks to the ability of the remaining cells to start migrating, collectively, to seal the breach. Specialised migratory cells called leader cells … read more

---

Help support non-profit medical journalism. If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

WOUND CARE Q&A from Podiatry Today
Windy Cole, DPM, CWSP, Barbara Aung, DPM, DABPM, CWS, FAPWHc, Matthew Garoufalis, DPM, FASPS, FACPM, CWS, FFPM RCPS (Glasg), Brian Lepow, DPM, DABPM, and Eric J. Lullove, DPM, CWSP, DABLES, FAPWHc

 

Over the past several years, artificial intelligence (AI)-based innovation in the medical field has emerged, including in various types of imaging. How might such technology apply to the field of wound care? In this edition of the Wound Care Q & A column, the panelists share their experiences and thoughts on if AI could bring a new era of improved outcomes … read more

---

Help support non-profit medical journalism. If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

18-19 May 2022 – Glasgow, UK
We believe that skin health and wound healing is everyone’s business and that change happens when we work together, not in silos.

We believe that skin health and wound healing is everyone’s business and that change happens when we work together, not in silos. Come to our annual face to face conference and you can join our community and listen to live lectures, interviews and discussions, take part in workshops, visit industry exhibition booths, network with colleagues and speakers and join the live conversations during the sessions.

Our conference really is space where professional connections are made, ideas are shared and collaborative action happens … read more

---

Help support non-profit medical journalism. If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.
 

Cellular and/or tissue-based products (CTPs) comprise an exciting and emerging technology in wound care. Deep and large wounds require more than just a standard dressing, topical ointments, and time. Wounds that penetrate the reticular dermis and below (deeper than ~0.57 mm) require additional scaffolding to support wound closure and prevent significant scarring.1 CTPs provide this scaffolding as well as naturally occurring chemicals and cells that support wound healing … read more

---

Help support non-profit medical journalism. If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.
 

March 16-19, 2022
Cedarbrook Lodge
St. Anne’s Hospital
Up to 18 CECH– Lectures (3/17-18)
Up to 8 CECH—Labs (3/19)
The 5th Annual Seattle Lower Extremity Surgery Symposium—SLESS offers continuing medical education on surgical techniques for lower extremity trauma and reconstruction. SLESS is a 3-day course, featuring two days of didactic lectures held at the Cedarbrook Lodge, 5 minutes from Seatac airport and one day of cadaveric skills sessions held at nearby St Anne’s Hospital 5 minutes’ drive from the hotel . Learn from a faculty of leading (MD and DPM) lower extremity surgeons … read more

---

Help support non-profit medical journalism. If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.
 

Education for pressure ulcer assessment and prevention is essential to ensure that patients receive safe, effective, harm-free care. Aligning an effective care bundle with the best possible evidence-based practice helps to safeguard patients by reducing the risk of this classic avoidable harm.
Pressure area care … read more

---

Help support non-profit medical journalism. If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.
 

It is estimated that one in four people with diabetes will have a diabetic foot ulcer during their lives, as a result of a combination of diabetes-related complications. Development of infection in a diabetic foot ulcer may be limb- or life-threatening. However, with good diabetes management and regular assessment this can be prevented … read more

Swift Medical, the global leader in digital wound care technology, is launching an innovative product that will revolutionize the future of healthcare … Today at 2pm EST / 11am PST, Swift Medical’s co-founder and CEO Carlo Perez will host a live broadcast from the TIFF Bell Lightbox in Toronto. At this event, Swift Medical will unveil a first-of-its-kind technology that will allow patients to access hospital quality care from anywhere and empower clinicians to prevent wounds before they even happen … Chronic wounds are one of the largest public health crises worldwide, with more than 8.2 million patients suffering from chronic wounds in North America alone. As rates of obesity, diabetes and other chronic conditions skyrocket, the number of patients at risk of developing chronic wounds will continue to rise … read more

Debridement is a key component of wound bed preparation for acute and chronic wounds because it helps to improve conditions at the wound bed to encourage healing. This, in turn, helps to reduce the risk of infection and improve patient quality of life.
Debridement … read more

Biofilm is thought to be present in all chronic wounds. Understanding what biofilm is and how to manage it is important to avoid delayed healing.
Biofilm … read more

This module aims to make clinicians aware of:

• The importance of skin health and what makes it vulnerable to damage.
• The damage that can occur when using medical adhesives and improper removal techniques.
• The impact that MARSIs (medical adhesive-related skin injuries) can have on patients.
• Ways to reduce the risk of MARSIs by providing appropriate treatment for at-risk patients groups.

… read more

Chronic wounds affect nearly 15% of Medicare patients (8.2 million people) and may cost as much as $96.8 billion per year. The most common are not venous or diabetic, even though they are the most often studied in prospective trials. The most common chronic wounds are surgical incisions that dehisce and the “wounds with no name” due to the patients’ underlying medical conditions. That is because wounds are not a disease – they are a symptom. The US Wound Registry (USWR), a 501 (c)(3) non-profit organization, has been a patient registry since 2005. Since 2014, the USWR has been recognized by the Centers for Medicare and Medicaid Services (CMS) as a Qualified Clinical Data Registry (QCDR) that collects medical and/ or clinical data for the purpose of improving the quality of patient care. While we understand that randomized, controlled trials are needed to demonstrate efficacy in a perfect world, real-world patients have an average of 6 serious co-morbid conditions and take 10 medications. These complicated patients are invariably excluded from clinical research studies, which makes it impossible to know what treatments work best. We believe the way to demonstrate effectiveness in the real world is by using real-world data … read more

A quick guide for registered managers of care homes

A healthcare professional should reassess a person’s pressure ulcer risk:

• after surgery or other investigation
• if they move to a different care setting
• if their underlying condition worsens
• after a change in their mobility.

If the person has several risk factors or a history of pressure ulcers, they should be assessed as being at high risk of developing a pressure ulcer. A trained healthcare professional should complete a skin assessment for anyone assessed as high risk … read more

An innocuous injury to his left little toe in late 2019 led to an infection that resulted in nine foot-related operations and five lower limb angioplasties in just over a year for Mr Toh Eng Cheng. His gangrenous toe had to be amputated, and another six later, to curb a recurrence of diabetic foot ulcers, but the 52-year-old counts himself lucky. “I could have lost the lower part of my leg or maybe the whole leg,” said the former security supervisor, who has three toes left on his right foot. “Of course, I did not like the idea of amputating my toes at first,” he told The Straits Times. “But if I didn’t accept it, then who knows, I might not be talking to you now,” he said. He added that he is glad he is still able to walk without the need for a walking frame or walking stick … read more

With the removal of government restrictions, telehealth codes are more usable and lucrative. CarePICS has taken advantage of these evolving rules to offer providers better wound care options … Do you ever wish a patient could send you a picture of their wound or rash AND you can bill for it? … read more

Foundations of Best Practice for Skin and Wound Management is a comprehensive document intended to help health-care professionals in the prevention and management of wounds … Developed by teams of interprofessional experts with a deep wealth of knowledge and experience, the chapters that make up Foundations have been built using a rigorous process of researching, writing and reviewing. Each chapter provides a best practice approach to the prevention and management of a particular wound type, except the first two, which offer a broad overview of skin physiology and wound healing and the prevention and management of wounds in general … order

A new study, “An Economic Evaluation of the Impact, Cost, and Medicare Policy Implications of Chronic Nonhealing Wounds,” published in the International Society For Pharmacoeconomics and Outcomes Research’s Value in Health journal (Jan. 2018) demonstrates the economic impact and full burden of chronic nonhealing wounds in the Medicare population. The study analyzed the Medicare 5% Limited Data Set for CY2014 to determine the cost of chronic wound care for Medicare beneficiaries in aggregate, by wound type, and by setting. Topline findings show that chronic wounds impact nearly 15% of Medicare beneficiaries … read more

An Iranian knowledge-based company has produced advanced wound dressing products, with structures similar to human skins
Wound dressings are important because wounds and damaged tissues go through a relatively-complicated and time-consuming process to heal. And using low-quality products could lead to infection or scars on the skin after wounds heal.

The products manufactured by Teba Zist Polymer (Treetta) company, after eight years of research and development, use a host of technologies to ensure quick and seamless healing of wounds … read more

Novel lysin Abp013 has shown promising antimicrobial ability against Acinetobacter baumannii and Klebsiella pneumoniae

Researchers from the Antimicrobial Resistance (AMR) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, alongside collaborators at Nanyang Technological University, have identified a novel phage lysin – Abp013 – that could be used as an alternative antimicrobial agent against two of the most deadly bacteria: Acinetobacter baumannii and Klebsiella pneumoniae. The study is supported by the National Research Foundation (NRF) Singapore, under its Intra-CREATE Collaborative Seed Grant … Antimicrobial resistance remains an ever-growing threat to humankind, and an increasing number of people die each year from superbug infections. The development of new bacteria-killing agents is crucial, and lysins have shown great promise in treating deadly chronic wound and lung infections against which no antibiotics are effective … read more

Research project award is for the development of Nexobrid as a non-surgical solution for field care
YAVNE, Israel, February 17, 2022 — MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio therapeutic solutions for tissue repair and regeneration, today announced that the U.S. Department of Defense (DoD), through the Medical Technology Enterprise Consortium (MTEC), has awarded MediWound a $1.7 million research project for the development of NexoBrid® as a non-surgical solution for field-care burn treatment for the U.S. Army (the “MTEC Research Project Award”).

“We are privileged to join forces with the U.S. DoD, supporting its goals of improving treatment outcomes and saving lives of service members who suffer traumatic burn injuries in the battlefield,” said Sharon Malka, Chief Executive Officer of MediWound. “This non-dilutive funding provides important recognition of NexoBrid’s merits as a non-surgical, easy-to-use, effective solution for eschar removal of severe burns and highlights its potential role in treating severe burn injuries in the field as early as the point of injury. We thank the U.S. Army Medical Research and Development Command (USAMRDC) for the award and look forward to working with them to have NexoBrid available for military use by the U.S. Army.”

“The military services require simple and effective non-surgical solutions to treat severe burn patients as close to point of injury as possible. MTEC is excited to support MediWound’s effort to advance an effective non-surgical debriding solution for far forward burn treatment to benefit U.S. service members. This work could result in a transformational change to the current standard of care of burn injuries,” stated Lauren Palestrini, PhD, MTEC Director of Research Programs … read more

The Alliance submitted a letter requesting that Noridian revise it Wound and Ulcer Care LCD (L38904) and LCA (A58567) to ensure that that CPT and HCPCS code descriptors are correct and to update incorrect/outdated terminology within the policy. The Alliance submitted a detailed list of suggested revisions … read more (available to Alliance members only)

By reporting MIPS through the US Wound & Podiatry Registries, you provide data that builds predictive wound healing models that improve patient outcomes … read more

Adults with diabetic foot ulcers and peripheral artery disease who receive revascularization surgery are at no greater risk for amputation or death following endovascular surgery compared with open vascular surgery, according to findings published in the Journal of Diabetes and its Complications … “The present large cohort study showed in a propensity score-adjusted analysis that there was no difference in amputation-free survival in patients with diabetic foot ulcers and peripheral arterial disease regardless of whether endovascular or open vascular surgery was chosen as first-line vascular intervention,” Talha Butt, MD, of the department of cardiothoracic and vascular surgery at Skåne University Hospital in Sweden … read more

FDA Recognizes Products as Minimally Manipulated, Homologous Use HCT/Ps
Amnio Technology, a global leader in the development of and distribution of amniotic tissue allografts is announcing the launch of two new PalinGen® membrane products, PalinGen® Dual-Layer Membrane and Dual Layer PalinGen® X-Membrane. The new allografts, like the entire family of PalinGen® membrane products, are minimally manipulated, homologous use and chorion-free. The dual-layered nature of the allografts allow for unidirectional application with two outward facing epithelial sides. The proprietary Advantek® process used to manufacture PalinGen® membranes preserves the extracellular matrix components and regulatory proteins present in amniotic tissues. Preserving the characteristics of the natural tissue aids in wound management.

PalinGen® Dual-Layer Membrane and Dual Layer PalinGen® X-Membrane are indicated for patients suffering from non-healing acute and chronic wounds as well as complex and/or open surgical wounds and burns.

Senior Director of New Product Development, Robert Diller, PhD, shared his insight into the motivation for developing a multilayered amniotic product, “The PalinGen® Dual layer membranes have increased durability and slower resorption, which makes them ideal for use in robotic and other surgical applications” … read more

growth factor dressings in the healing rate of diabetic foot ulcer: A randomized clinical trial
In patients having diabetic foot ulcers, a better-improved healing results from dehydrated amnion dressing than platelet-derived growth factor dressing and surgical debridement … This is a multi-arm parallel-group randomized trial including 243 patients with a minimum 4-week medical history of diabetic foot ulcers with Wagner’s grades 1 and 2, no infection, and adequate tissue blood flow … They were randomized to one of three 81-person groups: surgical debridement (the standard method), dehydrated amnion dressing, or platelet-derived growth factor dressing; and were followed up for 12 weeks … Regarding the type of ulcer, the area of ulcer, Wagner’s grade, the period, and the ulcer’s size, all three study groups were comparable … read more

TissueTech, Inc.—a pioneer in the clinical application of cryopreserved human birth tissue products to treat ocular surface disease and disorders, chronic wounds, and musculoskeletal conditions—has unveiled a corporate rebranding, including a name change and a new logo. BioTissue, Inc. and Amniox Medical, Inc. will now both be known under a single commercial, customer facing entity, BioTissue, Inc. … With three decades of continual advancements in regenerative medicine, BioTissue has been a clear leader in the ocular space. By adopting the BioTissue name across the entire organization, the company will also reflect that innovative heritage and promise in its surgical business, which was previously known as Amniox Medical … “For years, health care professionals have known our products—regardless of their specific applications—for providing mother nature’s most natural gift of healing so their patients can get back to the lives they love,” said Ted Davis, president and CEO, BioTissue. “Our new, unified brand supports our entire pipeline of human birth tissue products to aid the treatment of wounds, musculoskeletal conditions, trauma-induced injuries, ocular surface disease, and burns.” … read more

A multidisciplinary team of medical professionals developed guidance for healthcare professionals outlining the importance of nutrition therapy to support wound healing for foot ulcers … The guidance provides expert consensus regarding how nutrition from arginine, glutamine, hydroxymethylbutyrate (HMB), and micronutrients can help improve wound-care therapy for people living with diabetes who are more likely to develop foot ulcers … read more

APMA works tirelessly to advocate for the podiatric medical profession. Over the past year, APMA has been successful in ensuring podiatrists receive equitable reimbursement, and patients have full access to care provided by podiatrists. Recent successes include:

HealthNet Federal Services (HNFS), the TRICARE administrator for the West Region, agreed to APMA’s previous request, and now permits podiatrists to order non-invasive vascular or arterial studies for TRICARE beneficiaries … read more

Compared to prior to the pandemic, fewer patients consulted their primary physician for changing wound dressings and more changed the dressings themselves or were assisted by their family members. 13% of patients avoided doctor visits due to fear of COVID-19 and 26.1% minimised doctor visits … The Dermatology Life Quality Index showed a moderate to very severe impact on patients’ Quality of Life (mean score = 10.06). Only one patient used telemedicine. Due to limited access to primary care and fear of COVID-19, the pandemic had a detectable impact on the hospital management of patients with HS in our facility. Telemedicine still plays a negligible role in primary wound care … read more

In November 2019, Alessandra Mascaro was observing a community of chimpanzees in the Loango National Park in Gabon as part of her volunteer service with the Ozouga Chimpanzee Project when she noticed some unusual behavior. A chimp named Suzee was inspecting a wound on the foot of her son, Sia. Suzee suddenly caught an insect from a nearby leaf, put it into her mouth for a moment, and then pressed it to Sia’s wound.

Mascaro caught the unusual interaction on video and forwarded it to two scientists on the project: Tobias Deschner, a primatologist with the Ozouga Chimpanzee Project, and Simone Pika, a cognitive biologist at Osnabrück University. The researchers thought the interaction could be suggestive of prosocial behavior among chimpanzees and the capacity for empathy—a question of heated debate in the field—and they spent the next 15 months looking for other examples of this type of wound-treating behavior … read more

Survival analyses of a large prospective cohort followed-up for 24-months
Researchers aimed at determining the factors that are independently linked with time-to-(being)-ulcer-free, time-varying effects and predict adjusted ulcer-free probabilities, in a large prospective cohort with diabetes-related foot ulcers (DFU) followed-up for 24 months … read more

It is a goal of the Wound, Ostomy, and Continence Nurses SocietyTM (WOCN®) to continuously improve the educational content of the Wound Treatment Associate (WTA®) and Ostomy Care Associate (OCA®) Programs as well as the resources available to all WOCN members. Additionally, it is a goal of WOCN to work at continuous improvement in the areas of diversity, equity, and inclusion. As such, we’d like to extend an invitation to our WOC nurse colleagues to submit photographs of wounds and ostomies, specifically representing individuals of diverse skin tone. We would also invite you to submit photos related to continence-related issues, also in diverse skin tones. A wide variety of photograph examples serve to improve the education of our members and other healthcare providers by ensuring competency in wound, ostomy, and continence (WOC) assessment for all individuals. In this way, the care of all individuals with wound, ostomy, and continence care needs can be improved … read more

A Blinded Prospective Cohort Study
The current clinical standard for diagnosing deep-tissue pressure injury (DTPI) is visual inspection. This method is subjective and only presents to the observer the external “picture;” deeper tissues are disguised from the observer. In contrast, long-wave infrared thermography (LWIT) can capture an image of the area of concern and detect tissue temperature relative to the level of tissue perfusion … To determine the efficacy of a handheld LWIT device and software solution as an adjunct to the current clinical standard of visual skin assessment to detect nonvisual pathophysiologic changes of DTPI … read more

Diabetic foot ulcers (DFU) are chronic wounds in the foot or feet associated with neuropathy and/or peripheral artery disease (PAD) of the lower limb in patients with diabetes mellitus. Reports from the Centers for Disease Control and Prevention show that in the United States there are nearly one in four adults living with diabetes, which indicates that a large number of Americans are at risk of DFU. DFUs will develop in up to 34% of patients with diabetes at some time in in their lives, and of those, approximately 15%–25% will require an amputation. Moderate or severe malnutrition has been identified in over half of patients with DFU, and malnutrition in DFU is correlated with increased lower-extremity amputation. Improvements in wound care therapy, including nutrition interventions, can reduce the financial burden of DFUs and increase life expectancy and quality of life … read more

Wound infection has a significant impact on wound healing potential. When managing a wound, the first step is to determine if you are looking at an acute or chronic wound infection. Acute wound infection can be devastating and is often an underappreciated clinical condition that has been reported to increase the cost of care by up to 70%. Chronic wound infections are microbiologically, immunologically, and clinically distinct from acute wound infections and require a different treatment strategy … register

Chronic wounds are a global medical problem closely linked to diabetes. Every year, two per cent of the US population suffers chronic wounds, many resulting in amputation because they do not heal naturally and are typically infected with antibiotic-resistant bacteria. Consequently, conventional treatment methods such as antibiotics are often not an option. However, start-up VulCur Medtech has now developed an automated laser solution writes the Technical University of Denmark in this press release … While competitors are focusing on surface treatment, VulCur MedTech’s treatment goes deeper, cleaning the wounds from the inside out using an automated laser device that kills bacteria while avoiding human cells … read more

The Summit will provide a critically needed multi-disciplinary meeting for payers, government agency policymakers, prominent researchers, wound care medical specialty societies, patient and clinical associations, wound care clinics and manufacturers to address the shared goals of:

• Addressing the current state of wound care research and clinical trial design
• Exploring solutions to address the limitations in the wound care evidence-base
• Communicating with payer medical directors on the development of coverage policies and the use of clinical practice guidelines in coverage decisionmaking
• Defining “next steps” to actualize solutions
• Participating in a uniquely intimate gathering of leading decisionmakers

… register

We will soon be relaunching the Wound Care Weekly newsletter to our list of 7,000 wound care and podiatry professionals. We are looking for sponsors to keep the lights on for WCW. In addition to the newsletter, sponsor exposure would include prominent website visibility (website gets close to 30,000 page views per month), Facebook header and sticky posts (FB page has 1,600 likes and followers) and LinkedIn posts (about 1,200 connections). I expect dramatic growth for web traffic from the newsletter based on activity from when it was previously active. Our latest media kit is below, let me know if you have any questions.
WCW-media_kit_2022.pdf
-Andy Durban

Contact Page

The Alliance spoke at the Dec. 1-2, 2021 HCPCS Public Meeting in support of the CMS HCPCS Workgroup’s preliminary coding decision to establish three new Level II HCPCS codes for non-pneumatic compression devices. “Including disparate devices into the same HCPCS code would severely limit the ability of CMS and other interested parties to collect data and assess the utilization, cost, efficacy and clinical outcomes of these new devices. Therefore, we are in agreement with the creation of three new K codes since it will allow CMS to establish appropriate product segmentation thereby avoiding issues related to data collection and analysis,” the Alliance told the Workgroup … read more

Healogics, the nation’s leading provider of advanced wound care services, as part of their 2022 Healing Can’t Wait program, is promoting awareness of heart health and its impact to wound healing through their seventh annual Heart Health Awareness campaign. Throughout Heart Health Awareness Month, Healogics will work to spread awareness about how cardiovascular diseases can affect the wound healing process.

An alarming 48 percent of Americans currently suffer from cardiovascular disease. Cardiovascular disease can take many forms:

• Coronary Artery Disease (CAD)
• Peripheral Artery Disease(PAD)
• Vascular Insufficiency Diseases

… read more

As part of a QCDR, the US Wound & Podiatry Registries serve many purposes:

Follow the natural history of a disease, estimate the magnitude of a problem, document the type of patients served, estimate complication rates, understand variations in outcomes, determine clinical effectiveness of treatments in the real world, understand cost-effectiveness, monitor safety, measure and improve clinical quality … read more

The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc22-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction … read more

One of the journal’s initial goals was to keep our readers abreast of the latest developments and research in our specialty field.1 The COVID-19 pandemic has resulted in the greatest generational threat to “in-person” wound care and patient visits. We have been challenged with the need for social distancing, quarantines, lockdowns, and limited visitation to healthcare facilities. Healthcare professionals, patients, and providers have been forced to find viable alternative methods of care delivery … read more

The non-invasive indicator, which is around the same size as one of our fingertips, is the first of its kind. It does not make any contact with the wound but detects the beginnings of infection by sniffing the air above it.

It can be added to already existing bandages and allows infections to be detected without taking off the dressing – something which can inhibit the healing process and increase the likelihood of wound infection … read more

A small dot that changes colour if a patient’s wound shows early signs of infection has been invented by scientists at Queen’s University Belfast … The non-invasive indicator does not make any contact with the wound but detects the beginnings of infection by sniffing the air above it – it is the same size as a fingertip … It is the first of its kind and is predicted to bring major benefits to healthcare, especially because it can be added to already existing bandages … read more

With wounds being a part of everyday life, it is important to evaluate the level of healing of individuals. This can vary due to conditions that slow down healing, such as diabetes and can be categorized into acute and chronic wounds … Acute wounds can take up to a number of months to heal; however, chronic wounds may extend to several years, with continued inflammation being a large issue … Approximately 300,000 people are hospitalized per year in the United States for acute wounds … read more

TissueTech, Inc., a pioneer in the clinical application of cryopreserved human birth tissue products to treat ocular surface disease and disorders, chronic wounds, and musculoskeletal conditions, has named Ted Davis as the company’s new president and CEO. Davis—a seasoned biologics and orthopedics executive—takes the helm of an emerging company experiencing exponential growth, succeeding TissueTech founder and former CEO Amy Tseng, who retired January 3. Tseng remains a member of the company’s board of directors … TissueTech, Inc. is an emerging biotechnology company and leader in regenerative medicine using human birth tissue. TissueTech’s pioneering amniotic membrane products are processed using its proprietary CRYOTEK® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. Today, TissueTech is breaking new ground with multiple Investigational New Drug clinical trials underway as the company pursues 351 biologics’ approval for products to treat patients’ unmet clinical needs. TissueTech is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 600,000 human implants with its products and published over 380 peer-reviewed studies supporting TissueTech’s platform technology. Learn more at https://tissuetech.com
… read more

WoundZoom Digital Wound Management solution now available on Epic’s App Orchard Marketplace

 

STEVENS POINT, WI – JANUARY 27, 2022 – Perceptive Solutions, Inc., developer of WoundZoom
Digital Wound Management, today announced its integration partnership with Epic and the availability of
WoundZoom in the Epic App Orchard marketplace. The purpose of this partnership is to provide a
seamless exchange of wound care data between WoundZoom and a facility’s Epic EHR system.
Perceptive Solutions joins the Epic App Orchard as a trusted integration partner so our customers can
leverage the benefits of WoundZoom while eliminating additional steps in their workflow. Data captured
using WoundZoom at the bedside, such as precise wound measurements, images, and clinical
assessments automatically sync to patients’ charts, creating a more efficient workflow and a complete
patient record in the EHR.

 

“Our innovative digital wound management solution enables clinicians to spend more time with patients
through automated charting, wound imaging and elimination of the manual measurement process. We are
excited to provide accessibility of WoundZoom to hundreds of healthcare organizations using EPIC,” said
Mark Lacerte, President of Perceptive Solutions. “The technology integration through Epic’s certification
process enables seamless and efficient data flow from our solution into Epic’s clinical charts. This enables
healthcare facilities to more efficiently share valuable wound care data between both clinical and
administrative team members within their EHR.”

 

About Perceptive Solutions
Perceptive Solutions modernizes the practice of wound care with technology-enabled systems designed to
increase clinical efficiency, improve care quality, and mitigate risk. Integrating smoothly with your EHR,
WoundZoom utilizes the latest AI and imaging technology to capture accurate wound images and
measurements from your smart device, automatically prompt and document appropriate actions, and
create a continuous, standardized clinical record across shifts, floors, and facilities. For more information,
visit https://perceptivesol.com/

 

Media Contact
Karen Guzdzial
Director of Marketing
(727) 225 7944
karen.guzdzial@woundzoom.com

On March 17, 2022, APMA will host the fourth installment of its Coding Basics Webinar Series, “Wound Care / Ulcer Debridement.” Sarah Abshier, DPM; Mitchel Hilsen, DPM; and Lawrence Santi, DPM, will present.

This content is available to APMA members only. If you are a member, please log in to see the full content.

An Overview of Scientific Evidence and Understanding Their Mechanism of Action
The skin is the largest organ in the human body, composed of the epidermis and the dermis. It provides protection and acts as a barrier against external menaces like allergens, chemicals, systemic toxicity, and infectious organisms. Skin disorders like cancer, dermatitis, psoriasis, wounds, skin aging, acne, and skin infection occur frequently and can impact human life. According to a growing body of evidence, several studies have reported that natural products have the potential for treating skin disorders. Building on this information, this review provides brief information about the action of the most important in vitro and in vivo research on the use of ten selected natural products in inflammatory, neoplastic, and infectious skin disorders and their mechanisms that have been reported to date. The related studies and articles were searched from several databases, including PubMed, Google, Google Scholar, and ScienceDirect. Ten natural products that have been reported widely on skin disorders were reviewed in this study, with most showing anti-inflammatory, antioxidant, anti-microbial, and anti-cancer effects as the main therapeutic actions. Overall, most of the natural products reported in this review can reduce and suppress inflammatory markers, like tumor necrosis factor-alpha (TNF-α), scavenge reactive oxygen species (ROS), induce cancer cell death through apoptosis, and prevent bacteria, fungal, and virus infections indicating their potentials. This review also highlighted the challenges and opportunities of natural products in transdermal/topical delivery systems and their safety considerations for skin disorders. Our findings indicated that natural products might be a low-cost, well-tolerated, and safe treatment for skin diseases … read more

Robert S. Kirsner, MD, PhD, discusses new and tried-and-true wound healing methods in his presentation at the Maui Derm for Dermatologists meeting.

Robert S. Kirsner, MD, PhD, chairman and Harvey Blank professor in the Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery at the University of Miami Miller School of Medicine in Miami, Florida, shares his pearls for greater efficacy in his presentation at the current Maui Derm for Dermatologists meeting held in Maui, Hawaii. His pearls included: letting evidence guide decisions, debriding the wound edge along with the wound, using microbes to improve healing, and more … read more

Diabetic foot (DF) is one of the most common complications of diabetes and is associated with high morbidity, disability, lethality and low cure-rate. The clinical diagnosis and treatment of DF need to be standardized. The Chinese Diabetic Foot Cell and Interventional Therapy Technology Alliance has released six editions of guidelines and standards for clinical diagnosis and interventional treatment of DF, which filled the gap in the domestic DF treatment standard and played an important role in improving the level of diagnosis and treatment in China. In line with the latest developments in diagnosis and treatment, the Alliance, along with other 89 institutions, developed and issued the new edition based on the sixth edition to help standardize the clinical diagnosis and treatment of DF in China … read more

We conducted a prospective, observational, single-center study without modification of care. All patients followed for a DFU in the study center between 15th April 2020 and 11th May 2020 were included. The baseline assessment occurred 4 weeks after the beginning of lockdown and the follow-up visit 4 to 6 weeks after easing of lockdown. The primary analysis was based on the SINBAD classification … read more

Due to the need for more information about Department of Defense sponsored wound healing research, the Wound Healing Foundation initiated the writing of this article. It briefly describes the Vision, Mission and Goals of the Department of Defense Strategic Medical Research Plan. It also describes the current objectives of Department of Defense research funding and where to access this information in detail. The grant cycle, the timing of request for proposals and some of the specifics of their requirements are also mentioned. A brief discussion of budgeting and overhead is also included … read more

A Randomized Controlled Trial in Comparison With Conventional Methods
Diabetic foot ulcers (DFUs) are a global burden on health care systems. Despite the availability of various treatment modalities, many DFUs do not heal. Nonhealing wounds can lead to various complications, which add to significant morbidity in terms of the degree of moisture retained in the dressing, pain, foul order, and restriction of daily activities. A different treatment modality that can promote the wound healing process earlier (and is cost-effective, easy to use, and readily available) may be necessary to consider. Objective. The purpose of the current study was to demonstrate the efficacy of ultrathin skin grafting (UTSG) in the early healing of DFUs in terms of cost-effectiveness, reduced total number of hospital visits, and final wound outcome (ie, limb salvage rate). Materials and Methods. A randomized controlled trial was conducted in which 52 patients were treated with either UTSG … read more

Three rising wound care clinicians receive up to $1,500 each
KOKOMO, Ind., Jan. 25, 2022 /PRNewswire/ — The International Alliance of Wound Care Scholarship Foundation® has awarded inaugural scholarships to three recipients to commence their scholarship award program! … These scholarships are awarded to health care professionals for advanced wound care education and certification. This aids IAWCSF® in its purpose to help reduce the U.S. and global burden of wounds and associated costs by creating a larger number of providers who are educated specifically in treating wound care issues. After a thorough evaluation and assessment by the IAWCSF® Scholarship Review Board, three scholarship recipients were selected as follows … read more

 

The International Alliance of Wound Care Scholarship Foundation®

AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that six abstracts highlighting the clinical benefits of the RECELL® Autologous Cell Harvesting Device (RECELL® System) have been accepted at the 44th Annual John A. Boswick Burn & Wound Care Symposium. The international conference will be held in Maui, Hawaii, January 22-27, and covers the latest advancements in burn care, wound healing, and infection control … read more

The last issue of the year for Podiatry Management is typically dedicated to diabetes. Consistent with that, this article will expand on this issue’s article on PFA (partial foot amputation) written by Jeanette Smith … Devices typically used for patients with PFA range from stuffing a block of materials (toilet tissue, paper towels, rags, etc.) into the toe box of the shoe to a sophisticated hybrid lower extremity prosthetic prescribed by a physician. This article will provide some basic information on why it is important to provide the proper device … read more

Medtronic has recalled 95,110 HawkOne Directional Atherectomy Systems because of the risk of the guidewire within the catheter moving downward or prolapsing during use, which may damage the tip of the catheter … The US Food and Drug Administration (FDA) has identified this as a Class I recall, the most serious type, because of the potential for serious injury or death … The HawkOne Directional Atherectomy system … read more

Hospital-acquired pressure injuries (HAPIs) have significant impacts on patient morbidity and mortality, with approximately 2.5 million patients treated for pressure-related injuries annually. This study aimed to describe the influence of a comprehensive wound care team on HAPIs over an 8-year period … read more

Transcript: Hello, my name is Dr Matthew Regulski. I’m the medical director for the wound Institute of ocean County, New Jersey, and senior partner at Ocean County Foot & Ankle Surgical Associates … I want to bring to your attention today about a new fast filming, forming silicone that I think has made significant progress in the treatment of both chronic and acute wounds. I’ve been in practice for 17 years and I treat chronic wounds of all types. This has made a substantial impact on the treatment of very hard-to-heal chronic wounds … watch

Friday, February 18, 2022 | 9:00AM – 4:20PM EST
Our seminar is both virtual and immersive. With a focus on applying tomorrow what you learn today, this unique experience enables you to participate in your own learning through exploration of case scenarios and interactive exercises … Effective wound prevention and management in the post-acute care setting is essential to reducing unnecessary hospital readmissions and improving patient outcomes … register

To present the results of a scoping review exploring chronic wound care telemedicine before and during the pandemic, including the characteristics of the models implemented … This continuing education activity is intended for physicians, physician assistants, nurse practitioners, and nurses with an interest in skin and wound care… read more

easy-to-obtain clinical variables
We used data from a prospective analysis of 304 people with foot ulcer history who had 18-month follow-up for ulcer outcome. Demographic, disease-related and organization-of-care variables were included as potential predictors. Two logistic regression prediction models were created: model 1 for all recurrent foot ulcers (n=126 events) and model 2 for recurrent plantar foot ulcers (n=70 events). We used 10-fold cross-validation, each including five multiple imputation sets for internal validation. Performance was assessed in terms of discrimination using area under the receiver operating characteristic curve (AUC) (0–1, 1=perfect discrimination), and calibration with the Brier Score (0–1, 0=complete concordance predicted vs observed values) and calibration graphs … read more

ROCHESTER, N.Y., Jan. 24, 2022 /PRNewswire/ — To provide a growing number of patients with advanced regenerative wound therapies, Aedicell secured a Group Purchasing Agreement with Premier, Inc. making its skin substitute product Dermavest® available nationally to Premier alliance members. To accommodate the expected demand, Aedicell announces plans for a new production facility located in Cape May County, NJ, in addition to its American Association of Tissue Banks certified facility in Rochester, NY.

Premier, Inc. is a leading healthcare improvement company, uniting an alliance of more than 4,400 U.S. hospitals and health systems and approximately 225,000 other providers and organizations to transform healthcare.

“We’re here to transform the lives of people needing skin substitutes by transforming human tissue into therapies,” said Aedicell CEO Ted Burke. “This Premier Agreement will make our clinically proven therapies with enhanced patient outcomes available to more people at a lower cost, and our new facility in New Jersey will enable us to meet the expected demand for our products.” … read more

The inclusion of a certified wound and skin care nurse on a multiprofessional prone-positioning team significantly reduces the odds of pressure injuries developing in patients hospitalized with severe COVID-19, according to a study published in the January issue of the American Journal of Critical Care … Connie Johnson, R.N., from Penn Medicine Princeton Health in Plainsboro, New Jersey, and colleagues evaluated the association between including a certified wound and skin care nurse on a multiprofessional pronation team and the prevention of pressure injuries … read more

Delivering immunosuppressant treatment via targeted nanoparticles could open the door to a long-lasting cure for type 1 diabetes. Transplanting insulin-producing cells is a promising approach to treat the disease; however, it is plagued by issues of immune rejection. In a new study, published January 17 in Nature Nanotechnology, mice treated with a reengineered therapy could tolerate a transplant for much longer with fewer side effects … For the 1.6 million people in the U.S. living with type 1 diabetes, keeping the body’s blood sugar levels within the right window at all times can be an ongoing challenge … read more

Frustrated with a chronic wound that refuses to close? Or stay closed? It’s time you cashed in on the power of protein … Your body is programmed to heal, over and over again. Even in the face of diabetes and artery/vein diseases … So how can you speed up the body’s natural healing process? By listening to what your body is asking for. And when you have a wound, your body is craving protein … Healing the body with food isn’t about using “natural” foods on an open wound. Raw honey, apple cider vinegar, tea bags, coconut oil, and “miracle” food don’t belong on your wound. They post a huge risk of infection and moisture imbalance, which will slow healing … read more

Researchers aimed at ascertaining if higher all-cause rates of mortality and resource utilization are recorded during periods of diabetic foot ulceration. In addition, an episode-of-care model for diabetic foot ulceration has been developed and validated.

• The Medicare Limited Data Set between 2013 and 2019 was analyzed for retrieval of data for this study.
• Episodes-of-care were defined by clustering diabetic foot ulcer linked claims such that the longest time interval between consecutive claims in any cluster did not extend beyond a duration which was adjusted to match two characteristics of foot ulcer

… read more

A new bandage-type dressing for wounds, which has been made from plants, could be used to help them heal faster, a researcher in Oman has discovered … Saied Vakilian, a researcher at the Laboratory for Stem Cell and Regenerative Medicine at the Natural and Medical Sciences Research Centre at the University of Nizwa, led a team that used compounds made from two medicinal plants to help wounds heal faster … “This winning project aimed to evaluate a bioactive multilayer wound dressing based on chitosan and alginate,” said Vakilian … “To enhance healing potential, dracaena cinnabari and aloe vera were loaded as separate layers into the scaffold. The bare and bioactive multilayered scaffolds were fabricated by an iterative layering freeze-drying technique.” … read more